1. Home
  2. AGIO vs USAC Comparison

AGIO vs USAC Comparison

Compare AGIO & USAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • USAC
  • Stock Information
  • Founded
  • AGIO 2007
  • USAC 1998
  • Country
  • AGIO United States
  • USAC United States
  • Employees
  • AGIO N/A
  • USAC N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • USAC Natural Gas Distribution
  • Sector
  • AGIO Health Care
  • USAC Utilities
  • Exchange
  • AGIO Nasdaq
  • USAC Nasdaq
  • Market Cap
  • AGIO 2.5B
  • USAC 2.9B
  • IPO Year
  • AGIO 2013
  • USAC N/A
  • Fundamental
  • Price
  • AGIO $24.46
  • USAC $23.46
  • Analyst Decision
  • AGIO Buy
  • USAC Hold
  • Analyst Count
  • AGIO 7
  • USAC 4
  • Target Price
  • AGIO $37.33
  • USAC $25.50
  • AVG Volume (30 Days)
  • AGIO 1.8M
  • USAC 309.5K
  • Earning Date
  • AGIO 10-30-2025
  • USAC 11-05-2025
  • Dividend Yield
  • AGIO N/A
  • USAC 8.86%
  • EPS Growth
  • AGIO N/A
  • USAC 43.67
  • EPS
  • AGIO N/A
  • USAC 0.81
  • Revenue
  • AGIO $44,791,000.00
  • USAC $991,507,000.00
  • Revenue This Year
  • AGIO $25.57
  • USAC $7.32
  • Revenue Next Year
  • AGIO $153.24
  • USAC $4.51
  • P/E Ratio
  • AGIO N/A
  • USAC $29.29
  • Revenue Growth
  • AGIO 36.26
  • USAC 6.66
  • 52 Week Low
  • AGIO $22.24
  • USAC $21.53
  • 52 Week High
  • AGIO $62.45
  • USAC $30.10
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 25.59
  • USAC 51.88
  • Support Level
  • AGIO $22.24
  • USAC $23.10
  • Resistance Level
  • AGIO $46.00
  • USAC $24.00
  • Average True Range (ATR)
  • AGIO 2.20
  • USAC 0.71
  • MACD
  • AGIO -1.86
  • USAC 0.06
  • Stochastic Oscillator
  • AGIO 8.76
  • USAC 64.29

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About USAC USA Compression Partners LP Common Units Representing Limited Partner Interests

USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services in several shale plays throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.

Share on Social Networks: